Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the safety of the combined drug approach
(anti-thrombin III, infliximab, apotransferrin, human recombinant erythropoietin beta,
C1-inhibitor, glutathione, alfa-tocopherol, melatonin and epoprostenol)aimed to reduce
ischemia-reperfusion injury during liver transplantation in eligible recipients.
Phase:
Phase 1
Details
Lead Sponsor:
Universitaire Ziekenhuizen Leuven
Treatments:
alpha-Tocopherol Antithrombin III Antithrombins Epoetin Alfa Epoprostenol Infliximab Melatonin Tezosentan Tocopherols Vitamin E